• Akshay Khatri, Abhinav Agrawal, Rutuja R Sikachi, Dhruv Mehta, Sonu Sahni, and Nikhil Meena.
• Department of Pulmonary, Critical Care and Sleep Medicine - Northwell Health, 410 Lakeville Rd., Suite 107, 11040 New Hyde Park, United States. abhinav72@gmail.com.
• Adv Respir Med. 2018 Jan 1; 86 (1): 27-35.

AbstractInflammatory myofibroblastic tumors (IMT) of the lung, first reported in 1939, are considered a subset of inflammatory pseudo -tumors. They are a distinctive lesions composed of myofibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and eosinophils. IMTs may be benign, invade surrounding structures, undergo malignant transformation, recur or may even metastasize. They can occur due to a genetic mutation or can occur secondary to infectious or autoimmune diseases. Patients may be asymptomatic, or present with cough, hemoptysis, dyspnea, pleuritic pain, constitutional symptoms or pneumonia. In this article we review the pathophysiology, genetics, clinical presentation, imaging findings of IMT of the lung. We also discuss the various surgical and non-surgical treatment options and the prognosis associated with this disease.

21 keywords...

hide…